RxDoctor Payments Data

Richard Dougherty, MD

Internal Medicine · Charlotte, NCNPI 1629068515

Payments from drug & device makers

$18,318in general payments, 2019–2025

Across 1,043 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Novo Nordisk$2K
  • Boehringer Ingelheim$2K
  • Amgen$1K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • plus $8K from 42 others

What the payments were for

  • Food & beverage$17,85897%
  • Education$4002%
  • Gifts$590%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$18,318 in reported general payments places this provider in the 95th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$200,888
Medicare patients
265
Services billed
3,987

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol79$69,934
EliquisApixaban92$68,563
MounjaroTirzepatide59$68,532
JardianceEmpagliflozin58$53,073
MyrbetriqMirabegron38$25,418
XareltoRivaroxaban31$25,043
OzempicSemaglutide16$24,442
JanuviaSitagliptin Phosphate22$24,267
KerendiaFinerenone20$23,500
RybelsusSemaglutide13$22,636
Repatha SureclickEvolocumab28$21,734
GemtesaVibegron16$19,125
TrulicityDulaglutide12$16,143
VascepaIcosapent Ethyl13$10,804
Breo ElliptaFluticasone/Vilanterol15$6,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,210$84,67571 claims
AstraZenecaFarxiga$2,464$69,93479 claims
PfizerEliquis$811$68,56392 claims
Boehringer IngelheimJardiance$1,573$53,07358 claims
Novo NordiskOzempic, Rybelsus$2,250$47,07929 claims
Astellas Pharma US IncMyrbetriq$604$25,41838 claims
Johnson & JohnsonXarelto$1,198$25,04331 claims
MerckJanuvia$229$24,26722 claims
BayerKerendia$674$23,50020 claims
Sumitomo Pharma America, Inc.Gemtesa$339$19,12516 claims
GSKBreo Ellipta$246$6,62215 claims
AbbVieSynthroid$1,249$1,24311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →